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reports of hip protectors, which absorb or spread the
energy of a fall, were promising, but recent studies have
questioned their effectiveness.20 21
Conclusions
Hip fracture is the most common disabling injury and
cause of accidental death in older people. The
incidence and the public health and economic
consequences of this injury have risen as the
population has aged, and this is expected to continue
for the foreseeable future.
The prevention and management of hip fractures
involves a wide range of disciplines, and most people
who sustain the injury require surgery followed by a
period of rehabilitation. The complexity of care
needed for hip fractures makes the condition a real test
and a useful marker of the integration and effective-
ness of modern health care.
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Summary points
Hip fracture is the most common cause of acute orthopaedic
admission in older people
Treatment is generally surgical to replace or repair the broken bone
Mortality is 5-10% after one month and about 30% after one year
Some loss of function is to be expected in most patients
Multidisciplinary rehabilitation is needed for the patient to return
home
Ways to reduce the risk of further fracture should be considered
Corrections and clarifications
Minerva
Minerva apologises for nearly launching a health
scare. As many readers have pointed out, she
slipped up somehow in her assertion that long
term use of antiepileptic drugs is associated with an
increased risk of cancers, particularly in women
(BMJ 2006;332:1282, 27 May). The source article
(Neurology 2006;66:1318-24) quite clearly refers to
a risk of fractures, not cancer.
Selective serotonin reuptake inhibitors (SSRIs) and
suicide in adults: meta-analysis of drug company data
from placebo controlled, randomised controlled trials
submitted to the MHRA’s safety review
The authors of this article published last year,
David Gunnell and colleagues, have alerted us to
an error in the abridged version of their paper
(BMJ 2005;330:385-8). In the table, the correct
estimate for the pooled odds ratio for self harm
from the bayesian random effects meta-analysis for
non-fatal self harm in relation to use of selective
serotonin reuptake inhibitors (excluding
paroxetine) is “1.57 (credible interval 0.99 to
2.55)”—not 1.51 (0.95 to 2.49). This matches the
values given in the abstract and in the results
section of the paper.
Randomised, controlled trial of alternating pressure
mattresses compared with alternating pressure overlays
for the prevention of pressure ulcers: PRESSURE
(pressure relieving support surfaces) trial
An editorial misunderstanding during the proof
stage led us to inflate some values in this paper by
Jane Nixon and colleagues (BMJ 2006;332:1413-5,
17 Jun). In table 4 of the full version on bmj.com
(table 2 of the abridged version), the haemoglobin
levels on admission or preoperatively should be
0.89 (0.82 to 0.97) [not 8.9, 8.2 to 9.7], and the
corresponding P value should be 0.01 [not 0.1].
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